Outset Medical Inc. reported its financial results for the full year ended December 31, 2025. Total revenue for the period was USD 119.48 million, with product revenue at USD 84.81 million and service and other revenue at USD 34.67 million. Cost of product revenue was USD 43.77 million. The company noted a loss on extinguishment of a term loan related to the repayment of the SLR Term Loan in January 2025, which included final payment and termination fees. Interest income and other income, net, primarily consisted of returns from cash, cash equivalents, and short-term investments, while interest expense reflected charges from outstanding debt and amortization of the associated debt discount. The provision for income taxes was primarily related to foreign taxes in Mexico, with a full valuation allowance for deferred tax assets, including net operating loss carryforwards and tax credits mainly associated with research and development. Outset Medical continues to focus on its equity incentive plan and employee stock purchase plan to attract and retain talent. The company also highlighted its approach to revenue recognition, particularly regarding multiple performance obligations in its contracts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-051278), on February 13, 2026, and is solely responsible for the information contained therein.